Sales Force Restructuring Strategy For A New Oncology Indication Launch In The US

As per the WHO, cancer is the 2^nd leading cause of death globally, resulting in an estimated 9.6 million death in 2018. Approximately 300,000 new cases of cancer are diagnosed annually among children below 19 years of age.¹

With the rise of specialty pharma, the interactions between sales reps and healthcare stakeholders are becoming more profound, more productive, and much more scientific. As a result, pharma companies would not only need to come up with better products or therapies but will also need to assess their overall go-to-market strategy. It will better suit the product launches, making it successful and increasing the sales of current portfolios.

Axtria brought its considerable expertise in Promotion Response Model (PRM), and Sales Force Structure and Strategy (SFSS) projects to make the engagement highly successful. Axtria recommended the optimal sales force size and structure for different scenarios based on future market events and suggested multiple scenarios with revenue impact for the new indication on recommended sales force.

The transformation resulted in the following:

Efficient sales force size
for the brands

Making client capable of promoting its portfolio of drugs more effectively

Implementing the recommended sales force structure in the field

Read this illustration to know how Axtria helped a leading global biopharma client in building a go-to-market strategy with optimal sales force size and structure for a new oncology indication launch and made it successful in the market.

Contact us at insights@axtria.com with any questions.

1. WHO - Health Topics - Cancer